TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05483894

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg(Lipinon Tab. 10mg) once daily for 24 weeks for experimental group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg(Lipinon Tab. 10mg) once daily for 24 weeks for experimental group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 12 weeks and than Atorvastatin(Lipinon Tab. 10mg) for 12 weeks for control group
Study: NCT05787366

Intervention type: OTHER
Group type: OTHER
Intervention: usual care and follow-up by a nurse
Description: follow-up by a nurse and referral to a specialist(s) according to symptoms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Multifactorial Intervention (IMP)
Description: The content of the intervention is defined according to the result of the initial assessment in relation to the person's needs and the nature of his or her persistent symptoms. The patient, depending on his or her needs, may choose to participate in the following workshops :~* Knowledge of the disease and specific management, (led by the nurse)~* Covid-19 and anxiety/depression, (psychologist)~* Fatigue and adapted physical activities (video capsules)~* Covid-long and social link (professional and voluntary activities...) (social worker and/or nurse)~* The Recovery Café aims to provide a space for patients to listen to each other and share their experiences around themes related to the different dimensions of recovery: medical and psychological, economic, professional, social and existential.
Study: NCT05068492

Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: enhanced CT with standard procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: enhanced CT with standard procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: enhanced CT with standard procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: enhanced MRI with standard procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: enhanced MRI with standard procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: enhanced MRI with standard procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: HVPG
Description: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures

Intervention type: DIAGNOSTIC_TEST
Intervention: HVPG
Description: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures

Intervention type: DIAGNOSTIC_TEST
Intervention: HVPG
Description: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Digestive ultrasound with standard procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Digestive ultrasound with standard procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Digestive ultrasound with standard procedure
Study: NCT06045442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training
Description: The patients in the intervention group will receive 3 months of endurance training, 2x/week for 30 min. 5 min of this should be a warm-up, 20 min of exertion and 5 min of cool down. The warm-up and cool-down should be equivalent to a very light load (Borg scale 9), whereas the exertion phase should be exhausting for the patients (Borg scale 14-15).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual care
Study: NCT05697250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser power settings (Thulium Fiber Laser)
Description: Ureteroscopic lithotripsy using low power laser settings (0.4 - 0.6 J at 10 Hz corresponding to 2.4 - 6.0 Watts) or high power laser settings (0.4 J at 40 Hz, 0.6 J at 30 Hz or 0.8 J at 20 Hz corresponding to 16 - 18 Watts).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser power settings (Thulium Fiber Laser)
Description: Ureteroscopic lithotripsy using low power laser settings (0.4 - 0.6 J at 10 Hz corresponding to 2.4 - 6.0 Watts) or high power laser settings (0.4 J at 40 Hz, 0.6 J at 30 Hz or 0.8 J at 20 Hz corresponding to 16 - 18 Watts).
Study: NCT05201040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JETKNEE Synovial Fluid Supplement
Description: 2mL of JETKNEE Synovial Fluid Supplement

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2mL of normal saline
Study: NCT06079762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AGE SELF CARE group visit program
Description: AGE SELF CARE: Adaptation, Growth, and Engagement; Socialization, Empowerment, Learning, and Function; and Community Activation for Resilience in Elderhood, is a virtual group visit program. It includes education and behavioral change elements in the broad areas of self/health, home environment, and community. There are 8 weekly 90-minute virtual sessions facilitated by an aging expert (e.g., geriatrician). Examples of topics include Aging Well: The Power of Movement, People Can Change, Homes Can Too, and Social World.
Study: NCT06494306

Intervention type: BEHAVIORAL
Intervention: European Test of Olfactory Capabilities (ETOC)
Description: Investigators will collect the ETOC score in patient of both arms

Intervention type: BEHAVIORAL
Intervention: European Test of Olfactory Capabilities (ETOC)
Description: Investigators will collect the ETOC score in patient of both arms

Intervention type: BEHAVIORAL
Intervention: Standardized Hedonicity Test
Description: To smell 20 odorant solutions and for each odor and evaluate it along five dimensions: familiarity, hedonicity, edibility, desire to smell again, perceived intensity). Each dimension is assessed with a Likert scale (from 1 (not at all) to 9 (extremely))

Intervention type: BEHAVIORAL
Intervention: Standardized Hedonicity Test
Description: To smell 20 odorant solutions and for each odor and evaluate it along five dimensions: familiarity, hedonicity, edibility, desire to smell again, perceived intensity). Each dimension is assessed with a Likert scale (from 1 (not at all) to 9 (extremely))

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Patients with PTSD will have the following questionnaires : PTSD Checklist for Diagnostic and Statistical Manual (DSM)-V (PCL-5), Peri-trauma Dissociation Experience Questionnaire (PDEQ), Patient Health Questionnaire-9 (PHQ9), Snaith-Hamilton Pleasure Scale (SHAPS), Childhood Trauma Questionnaire (CTQ) and Apathy Evaluation Scale (AES)

Intervention type: BEHAVIORAL
Intervention: Odor / trauma association questionnaire
Description: Patients with PTSD will have Odor / trauma association questionnaire
Study: NCT05265156

Intervention type: OTHER
Group type: OTHER
Intervention: Plant based formula for children aged between 12 and 36 months
Description: Daily intake of plant based formula for 3 weeks (400ml-600ml per day).
Study: NCT06273475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted Training
Description: Gait training and functional strength training facilitated by body weight unloading robotic technology yielding a dynamic unloading force applied to the body centre of mass. Gait training will be conducted both on treadmill and overground. Functional strength training exercises include sit-to-stand, stair-walking, step-ups etc. The goal is to gradually reduce body weight unloading as participants progress through the intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Training
Description: Gait training and functional strength training facilitated without the use of body weight unloading robotic technology, thereby only allowing manual assistance from physiotherapists. The goal of training is the same as in the intervention group, however no body weight unloading device will be implemented in the active control group.
Study: NCT06372418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding peer support intervention
Description: In addition to support as currently recommended by the World Health Organization (WHO) and National IMAM guidelines, care givers will receive a homebased individualized face to face support provided by breastfeeding peer supporters and phone call support upto 7 weeks post hospital discharge.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Caregivers will receive post-discharge support as currently recommended by the World Health Organization (WHO) and national IMAM guidelines.
Study: NCT04823793

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool DNA methylation detection
Description: Stool specimens are collected from participants in the outpatient department or the inpatient department. Both FIT and stool DNA real-time PCR are performed simultaneously. To improve the sensitivity and specificity of the colorectal cancer screening, this study enrolls multiple candidate genes to distinguish whether the participant has a high risk of colorectal cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool DNA methylation detection
Description: Stool specimens are collected from participants in the outpatient department or the inpatient department. Both FIT and stool DNA real-time PCR are performed simultaneously. To improve the sensitivity and specificity of the colorectal cancer screening, this study enrolls multiple candidate genes to distinguish whether the participant has a high risk of colorectal cancer.
Study: NCT06015620

Intervention type: PROCEDURE
Intervention: Mini gastric bypass surgery
Description: Mini gastric bypass surgery is a common metabolic or bariatric surgery done world wide for patients suffering from morbid obesity not managed by non surgical modalities of treatment.
Study: NCT05509283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction
Description: Letter, patient portal, SMS and/or another modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction
Description: Letter, patient portal, SMS and/or another modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction
Description: Letter, patient portal, SMS and/or another modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction
Description: Letter, patient portal, SMS and/or another modality
Study: NCT04750577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 685509
Description: film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: film-coated tablet
Study: NCT06646224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorVad Percutaneous Ventricular Assist System
Description: The CorVad Percutaneous Ventricular Assist System provides circulatory support for patients with cardiogenic shock.
Study: NCT06646133

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D camera weight estimate
Description: Weight estimation using 3D camera system

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard methods of weight estimation
Description: Standard methods of weight estimation will be used
Study: NCT05218421

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid ultrasound
Description: Carotid ultrasound with flow and elastography (strain and shear wave) measurements will be performed maximally 2 weeks prior to the CEA. Ultrasound-based flow imaging will be repeated six weeks after the CEA to assess the hemodynamic consequences of the CEA procedure.

Intervention type: OTHER
Intervention: Biospecimen collection and examination
Description: The plaque excised during CEA will be histologically examined to assess the plaque composition, and therefore plaque vulnerability.

Intervention type: OTHER
Intervention: Blood sample collection
Description: In the first 20 included patients in the Radboudumc, a 10 mL blood sample will be collected during surgery via the arterial line that is applied for regular care.
Study: NCT06232317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Software
Description: The ReCognitionVR virtual reality software is delivered via an Oculus Quest 2 device. This three-dimensional simulated software was designed to improve attention and executive functions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Orientation Methods
Description: Standard-of-care methods to orient patients after surgery
Study: NCT06385197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App randomizing dosing regimen
Description: patients will receive their dimethyl fumarate treatment and the dose and time of administration will be determined using a designated app.
Study: NCT04836481

Intervention type: OTHER
Intervention: Serum Sample Collection
Description: Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.

Intervention type: OTHER
Intervention: Serum Sample Collection
Description: Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.
Study: NCT04789928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicins-EDTA
Description: Patients included in this study will receive daily injection (up to 10 days) of genta-EDTA-Na2 lock associated with systemic antibiotics.
Study: NCT05046431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2506
Description: 50mg/0.5mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU Simponi
Description: 50mg/0.5mL
Study: NCT05990959

Intervention type: OTHER
Intervention: No intervention for research purpose
Description: No any intervention will be applied under research purpose. All procedure or drugs would be given to the patient under best clinical judgment, not for research purpose.
Study: NCT05479591

Intervention type: DRUG
Intervention: IDegLira
Description: Participants will be treated with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia and independent from the decision to include the participant in the study.
Study: NCT05648240

Intervention type: OTHER
Intervention: Blood test
Description: Venous blood samples taken at the moment of colonoscopy to test for biomarkers

Intervention type: OTHER
Intervention: Blood test
Description: Venous blood samples taken at the moment of colonoscopy to test for biomarkers
Study: NCT06472999

Intervention type: PROCEDURE
Intervention: Nephroprotective measures
Description: Due to the observational design of the study, no study specific interventions are performed. The treatment of the patients is completely guided by the responsible physicians.
Study: NCT06286475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRG50635
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRG50635
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRG50635
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRG50635
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05814705

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein supplement
Description: Ready-to-drink protein beverage consumed once daily for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement with Urolithin A
Description: Ready-to-drink protein beverage with 1000 mg of Urolithin A consumed once daily for 28 days
Study: NCT06618807

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tPBM device
Description: The Neuro RX Gamma (version 2) delivers a synchronized pulse frequency of 40 Hz from all LED clusters. The gamma pulse frequency of 40 Hz has been demonstrated to attenuate amyloid beta proteins production in the hippocampus and modulate microglial activity resulting in increased scavenging of amyloid beta which may lead to improving cognition in MCI. Finally, the Vielight Neuro RX Gamma (version 2) has been designed to target the delivery of NIR energy to particular brain regions; specifically the default mode network (DMN). The active intervention device proceeds to deliver light to each LED at 40 Hz with a 50% duty cycle for 20 minutes and stops automatically. During the 20 minute treatment the power indicator LED on the controller flashes green at 40 Hz. The operator is notified that the treatment is finished when the power indicator LED on the controller stops flashing and the device beeps 2 times.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The sham device delivers infrared light for only a few seconds before stopping. The controller will still show a green light to maintain the study\&#39;s blinding. If the headset is removed, the device will emit a beep and cease functioning.
Study: NCT06389149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEAP therapy
Description: Knee bending from 90°-180° at 1Hz for 1 minute every 10 minutes during 2.5 hours of prolonged sitting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEAP therapy
Description: Knee bending from 90°-180° at 1Hz for 1 minute every 10 minutes during 2.5 hours of prolonged sitting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEAP therapy
Description: Knee bending from 90°-180° at 1Hz for 1 minute every 10 minutes during 2.5 hours of prolonged sitting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEAP therapy
Description: Knee bending from 90°-180° at 1Hz for 1 minute every 10 minutes during 2.5 hours of prolonged sitting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no LEAP therapy
Description: 2.5 hours of uninterrupted prolonged sitting (no movement)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no LEAP therapy
Description: 2.5 hours of uninterrupted prolonged sitting (no movement)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no LEAP therapy
Description: 2.5 hours of uninterrupted prolonged sitting (no movement)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no LEAP therapy
Description: 2.5 hours of uninterrupted prolonged sitting (no movement)
Study: NCT05553470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant
Description: 600 mg miricorilant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant
Description: 600 mg miricorilant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant
Description: 600 mg miricorilant
Study: NCT04116723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible brace
Description: Participants will be invited to undergo a fitting session of a flexible brace. After the fitting session, participants will join a two-hours wear trial of the flexible brace. Participants are required to wear the brace for two-hours and undergo assessments before and after the wear trial. The measurement outcomes of the assessment include 1) X-ray scan, 2) 3D body scan, 3) garment pressure, and 4) questionnaire.
Study: NCT06057714

Intervention type: COMBINATION_PRODUCT
Intervention: 19F MRI
Description: Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing
Study: NCT04159168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Affect Sensitivity Training (FAST)
Description: The FAST intervention program represents a novel computerized intervention for high-risk youth that strategically targets implicated facial affect sensitivity deficits directly via a computerized real-time automated feedback and incentive system to remediate callous-unemotional tendencies associated with behavioral dysfunction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Affect Sensitivity Training (FAST)
Description: The FAST intervention program represents a novel computerized intervention for high-risk youth that strategically targets implicated facial affect sensitivity deficits directly via a computerized real-time automated feedback and incentive system to remediate callous-unemotional tendencies associated with behavioral dysfunction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implicit Gaze Training task (Active control condition)
Description: This computerized task was developed to target implicit training of eye gaze but not facial emotion recognition per se via real-time feedback and incentives. On each trial, a fixation cross is followed by an emotional face with eyes directed either left, straight ahead, or right (balanced across expressions), followed by a response key. The child's task is to say which direction the eyes are looking (e.g., 1 or left). Stimuli are black and white standardized photographs of men and women models from the Ekman Pictures of Facial Affect each displaying the 3 gaze directions for 6 emotion expressions.